RecruitingNot ApplicableNCT05302583

Aromatherapy Inhaler Use for HSCT Distress

Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress

Sponsor

Stanford University

Enrollment

50 participants

Start Date

Jun 16, 2025

Study Type

INTERVENTIONAL

Conditions

Cancer Distress Aromatherapy Cancer Coping Hematopoetic Stem Cell Transplant

Summary

This randomized controlled trial will evaluate the feasibility and acceptability of an inhaled aromatherapy stick for patients during the acute inpatient phase after hematopoietic cell transplantation (HCT) . The study will also explore whether aromatherapy use is associated with short-term changes in patient-reported cancer-related distress and coping self-efficacy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Aromatherapy Stick and Standard of Care for people with aromatherapy, cancer coping, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAromatherapy Stick

Participants receive aromatherapy inhaler education and an aromatherapy stick for self-administered inhalation during the early post-transplant inpatient period. Aromatherapy use occurs on the assigned Inhaler Use Day (targeted for Transplant Day +1, +2, or +3) and is documented using an inhaler use log. Total exposure is limited to a maximum of 2 hours.

OTHERStandard of Care

Participants receive standard inpatient supportive care during the acute post-HCT period. No aromatherapy inhaler is provided.